Mesenchymal Stromal Cells from Osteoarthritic Synovium Are a Distinct Population Compared to Their Bone-Marrow Counterparts regarding Surface Marker Distribution and Immunomodulation of Allogeneic CD4+ T-Cell Cultures

Table 1

Surface marker expression and 7-AAD staining on bone-marrow (BM) and synovial membrane (SM) derived mesenchymal stromal cells (MSCs) from osteoarthritis patients, detected by flow cytometry at d0 before coculture. Results are displayed as % positive cells, means ± standard deviation. Wilcoxon signed rank tests were performed to compare two groups (BM-MSCs and SM-MSCs at day 0, d0 and d5 expression results, and d5 coculture and control results). Bold values are beyond the significance level of 0.05.

(a)

Day 0	BM-MSCs	SM-MSCs	Wilcoxon BM-MSCs/SM-MSCs
CD14	4.87 ± 2.44	7.26 ± 5.31
CD19	9.59 ± 8.67	11.79 ± 13.13
CD34	1.04 ± 0.45	1.47 ± 0.57
CD45	1.63 ± 0.61	1.91 ± 1.11
CD73	99.84 ± 0.15	99.95 ± 0.05
CD90	94.1 ± 4.3	98.01 ± 1.82
CD105	99.86 ± 0.12	99.69 ± 0.19
CD146	79.41 ± 7.49	15.95 ± 9.56
HLA-ABC	99.94 ± 0.04	99.92 ± 0.08
HLA-DR	52.38 ± 23.24	31.54 ± 23.13
7-AAD	8.27 ± 5.93	3.6 ± 2.84

(b)

Day 5	BM-MSCs/CD4+	Control BM-MSCs	Wilcoxon BM-MSCs d5-d0/d5-control
CD14	1.02 ± 0.24	1.17 ± 1
CD19	34.15 ± 16.55	39.26 ± 20.81
CD45	2.32 ± 0.64	1.46 ± 0.79
CD73	99.19 ± 0.33	99.72 ± 0.17
CD90	88.43 ± 8.99	94.24 ± 5.09
CD105	99.65 ± 0.20	99.78 ± 0.14
CD146	39.97 ± 18.13	53.25 ± 19.58
HLA-ABC	98.56 ± 1.95	98.63 ± 2.20
HLA-DR	71.13 ± 16.16	66.13 ± 18.34
7-AAD	5.06 ± 3.41	11.15 ± 8.91

(c)

Day 5	SM-MSCs/CD4+	Control SM-MSCs	Wilcoxon SM-MSCs d5-d0/d5-control
CD14	0.79 ± 0.12	0.79 ± 0.17
CD19	15.04 ± 11.42	16.71 ± 11.98
CD34	1.42 ± 1.43	3.05 ± 2.53
CD45	1.9 ± 0.53	1.3 ± 0.21
CD73	99.39 ± 0.29	98.56 ± 4.06
CD90	96.38 ± 2.96	98.59 ± 1.09
CD105	99.38 ± 0.35	99.67 ± 0.15
CD146	1.08 ± 0.56	1.93 ± 0.91
HLA-ABC	99.16 ± 0.33	99.01 ± 1.56
HLA-DR	42.53 ± 24.45	35.11 ± 21.60
7-AAD	1.44 ± 0.63	2.89 ± 2.36